YOLFTbeta
BioLineRx Ltd

BioLineRx Ltd

BLRX · NASDAQ · Healthcare / Biotechnology

1.30USD-0.05 (-3.70%)

Price History

Full chart

Market Stats

Previous Close1.35
Open1.37
Day Range1.30 – 1.54
52-Week Range2.15 – 4.56
Volume13.30K
Market Cap11.01M
P/E (TTM)0.00
Forward P/E93.46
EPS0.00
Dividend Yield0.00%
Beta0.69
50-Day Avg2.71
200-Day Avg2.85

About

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Philip A. Serlin CPA, M.B.A.
  • Employees20
  • HeadquartersModi?in Technology Park, Hevel Modi'in, Israel, 7177871, USA
  • Websitehttps://www.biolinerx.com

Leadership

  • Mr. Philip A. Serlin CPA, M.B.A.Chief Executive Officer · b. 1960
  • Ms. Mali Zeevi CPAChief Financial Officer · b. 1976
  • Dr. Ella Sorani Ph.D.Chief Development Officer · b. 1968
  • Mr. John LaceyHead of Corporate Communications & Investor Relations
  • Mr. Raziel FriedTreasurer & Budgetary Control Director

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-16.27M31.89M63.91M113.16M113.16M0000000004.80M28.94M1.19M
Growth (%)--+96.01%+100.38%+77.06%0.00%-100.00%---------+502.92%-95.89%
Cost of Revenue636.18K6.21M7.21M22.62M21.48M19.03M0440.89K481.89K480.68K451.00K940.00K934.00K702.00K654.00K3.69M9.26M758.97K
Gross Profit-636.18K10.07M24.69M-436.81K-395.18K-317.77K-268.37K-440.89K-481.89K-480.68K-451.00K-940.00K-934.00K-702.00K-654.00K1.11M19.68M430.39K
Gross Margin-61.86%77.40%-0.68%-0.35%-0.28%---------23.08%67.99%36.19%
Operating Expense32.65M26.18M20.98M15.93M20.75M16.69M16.99M15.76M16.03M24.76M25.15M27.17M21.99M24.07M28.50M50.80M40.09M10.80M
Operating Income-33.29M-16.11M3.70M-16.37M-21.15M-17.01M-17.25M-16.20M-16.51M-25.24M-25.61M-28.11M-22.93M-24.78M-29.16M-49.69M-20.41M-10.37M
Operating Margin--99.02%11.61%-25.61%-18.69%-15.03%----------1035.29%-70.52%-871.78%
EBITDA-31.42M-15.22M4.21M-15.00M-19.38M-16.69M-16.91M-15.77M-15.34M-24.80M-22.04M-22.65M-27.59M-25.37M-22.14M-57.09M3.92M-224.77K
EBITDA Margin--93.51%13.21%-23.47%-17.13%-14.75%----------1189.29%13.54%-18.90%
Net Income-32.06M-15.66M2.10M-13.19M-20.42M-17.64M-10.17M-14.40M-15.84M-24.35M-22.96M-25.45M-30.02M-27.05M-24.95M-60.61M-9.22M-1.18M
Net Income Margin--96.26%6.57%-20.63%-18.04%-15.59%----------1262.79%-31.86%-99.58%
R&D29.02M22.58M15.49M11.20M17.21M12.21M10.90M11.49M11.18M19.51M19.81M23.44M18.17M19.47M17.63M12.52M9.15M7.66M
R&D as % of Total Revenue-138.74%48.57%17.52%15.21%10.79%---------260.81%31.61%643.90%
Interest Expense--16.63K1.12M25.96K20.67K411.67K15.00K14.00K21.00K21.00K1.83M1.47M984.00K2.16M2.17M9.16M1.29M
Interest Expense % of Total Revenue--0.05%1.75%0.02%0.02%---------45.19%31.66%108.47%

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets30.64M42.02M43.66M29.34M24.31M19.95M36.17M51.30M38.94M60.97M56.23M53.57M47.29M81.39M76.38M63.92M38.91M40.90M
Total Liabilities9.89M10.88M6.40M6.81M9.34M8.27M4.40M3.69M3.91M8.08M14.91M20.19M25.26M13.30M25.54M50.70M25.45M17.56M
Total Equity20.75M31.13M37.26M22.53M14.97M11.68M31.77M47.61M35.03M52.88M41.32M33.38M22.03M68.09M50.84M13.22M13.46M18.20M
Cash15.99M27.95M31.55M8.69M18.29M8.87M5.78M5.54M2.47M5.11M3.40M5.30M16.83M12.99M10.59M4.25M10.44M3.25M
Total Debt--208.67K109.56K36.67K--437.00K343.00K250.00K8.73M10.46M7.68M4.65M12.32M11.59M15.04M10.15M
Net Debt-15.99M-27.95M-31.34M-8.58M-18.26M-8.87M-5.78M-5.11M-2.13M-4.86M5.33M5.16M-9.15M-8.34M1.74M7.34M4.60M6.90M

Cash Flow

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-27.96M-21.51M11.46M-11.22M-20.11M-20.23M-14.48M-14.17M-14.51M-20.55M-24.19M-22.67M-23.21M-23.57M-26.24M-22.61M-43.87M-8.14M
Investing Cash Flow-9.29M7.85M-8.32M-9.87M13.74M-5.69M-18.17M-15.60M9.30M-15.93M9.55M5.26M16.67M-38.22M4.01M1.44M29.37M-8.61M
Financing Cash Flow-24.87M215.62K-80.66K15.77M15.07M32.63M29.49M2.09M38.68M13.10M19.19M17.87M57.75M20.44M15.06M20.66M8.95M
Capital Expenditure908.63K59.83K660.94K284.81K176.39K117.16K178.48K2.72M55.00K4.24M10.22M73.00K97.00K97.00K316.00K297.00K54.00K25.20K
Free Cash Flow-28.86M-21.57M10.80M-11.51M-20.29M-20.35M-14.66M-16.89M-14.57M-24.79M-34.41M-22.74M-23.21M-23.67M-26.56M-22.91M-43.93M-8.16M
FCF to OCF103.25%100.28%94.23%102.54%100.88%100.58%101.23%119.19%100.38%120.63%142.23%100.32%100.00%100.41%101.20%101.31%100.12%100.31%

Earnings

Report DateSep 30, 2011Dec 31, 2011May 30, 2012Aug 15, 2012Nov 14, 2012Mar 12, 2013May 7, 2013Aug 6, 2013Nov 13, 2013Mar 17, 2014May 20, 2014Aug 6, 2014Nov 10, 2014Mar 23, 2015May 18, 2015Aug 20, 2015Nov 16, 2015Mar 10, 2016May 17, 2016Aug 11, 2016Nov 22, 2016Mar 23, 2017May 25, 2017Aug 8, 2017Nov 21, 2017Mar 6, 2018May 22, 2018Aug 13, 2018Nov 8, 2018Mar 28, 2019May 14, 2019Aug 6, 2019Nov 11, 2019Mar 12, 2020May 20, 2020Aug 6, 2020Nov 23, 2020Feb 23, 2021May 26, 2021Aug 18, 2021Nov 18, 2021Mar 16, 2022May 11, 2022Aug 16, 2022Nov 15, 2022Mar 22, 2023May 24, 2023Aug 30, 2023Nov 20, 2023Mar 28, 2024May 28, 2024Aug 15, 2024Nov 25, 2024Mar 26, 2025May 27, 2025Aug 14, 2025Nov 24, 2025Mar 23, 2026May 27, 2026Aug 31, 2026
EPS Estimate----150.00-144.00-4.20-120.00-90.00-108.00-2.25-54.00-86.60-99.00-3.60-19.20-32.00-51.00-36.00-1.15-44.00-44.00-48.00-0.85-33.00-31.50-37.50-42.00-36.00-33.00-1.39-30.00-24.67-2.00-0.66-33.00-24.00-13.60-9.73-7.47-4.60-5.00-0.14-6.00-5.20-4.53-0.09-5.60-6.80-8.40-0.16-11.60-5.60-4.40-0.03-1.06-0.53-0.54-0.77-1.04-0.30
EPS Actual-107.93-184.79-192.43-120.00-240.00-4.50-120.00-120.00-120.00-3.00-60.00-72.00-120.00-0.13-60.00-54.00-18.00-36.00-0.96-42.00-48.00-42.00-1.20-30.00-42.00-42.00-36.00-30.00-36.00-0.60-30.00-24.00-1.20-0.90-24.00-18.00-12.00-24.00-0.80-6.00-6.00-0.10-0.40-6.00-6.00-0.09-6.00-12.00-12.00-0.15-0.010.01-0.070.00-1.50-1.02-0.23-0.32-0.58-0.77
Surprise---20.00%-66.67%-7.14%0.00%-33.33%-11.11%-33.33%-11.11%16.86%-21.21%96.39%-212.50%-68.75%64.71%0.00%16.52%4.55%-9.09%12.50%-41.18%9.09%-33.33%-12.00%14.29%16.67%-9.09%56.83%0.00%2.72%40.00%-36.36%27.27%25.00%11.76%-146.66%89.29%-30.43%-20.00%28.57%93.33%-15.38%-32.45%0.00%-7.14%-76.47%-42.86%6.25%99.91%100.11%98.35%100.00%-41.57%-92.15%58.17%58.40%44.03%-156.67%
Timing---Pre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap11.01M
Enterprise Value7.40M
Trailing P/E0.00
Forward P/E93.46
PEG Ratio0.20
Price / Sales7.91
Price / Book0.89
EPS0.00
Book Value3.00
Revenue (TTM)1.39M
Gross Profit (TTM)1.11M
EBITDA-12.12M
Profit Margin0.00%
Operating Margin-1215.31%
Return on Equity-55.27%
Return on Assets-19.82%
Shares Outstanding4.37M
Shares Float4.11M
Beta0.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 22.00
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
1.34%
Insiders
3.43%
Retail / Other
95.23%

Top Institutional Holders

  • Citadel Advisors Llc
    14.80K0.31%
  • XTX Topco Ltd
    10.94K0.23%
  • Rhumbline Advisers
    2.35K0.05%
  • BNP Paribas Arbitrage, SA
    1.80K0.04%
  • Wells Fargo & Co
    1.75K0.04%
  • Citigroup Inc
    1.73K0.04%
  • UBS Group AG
    5290.01%
  • Banque Cantonale Vaudoise
    3210.01%
  • Goss Wealth Management LLC
    1070.00%
  • Morgan Stanley - Brokerage Accounts
    1000.00%
  • Advisor Group Holdings, Inc.
    260.00%
  • Rockefeller Capital Management L.P.
    120.00%
  • Danske Bank A/S.
    20.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    9990.04%

Stock Splits

  • Jan 30, 20251:40
  • Jul 15, 20191:15